<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02007577</url>
  </required_header>
  <id_info>
    <org_study_id>19254</org_study_id>
    <nct_id>NCT02007577</nct_id>
  </id_info>
  <brief_title>Beneficial Effect of Salicylates: Insulin Action, Secretion or Clearance?</brief_title>
  <official_title>Beneficial Effect of Salicylates: Insulin Action, Secretion or Clearance?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The possibility that obesity-associated inflammatory changes may play a role in the
      pathogenesis of type 2 diabetes (2DM) has led to increased interest in the possibility that
      salicylates might represent a useful treatment to improve glucose tolerance. Several studies,
      performed in patients with 2DM, as well as in nondiabetic, obese individuals, have
      demonstrated that salicylates have beneficial effects on glucose and insulin metabolism, but
      have not led to a coherent view as to the mechanism(s) involved.

      In this research proposal we will use specific methods to quantify insulin mediated glucose
      uptake (IMGU), glucose-stimulated insulin secretion rate (GS-ISR), and insulin clearance
      (I-Cl) in overweight/obese, nondiabetic, insulin resistant individuals. We will use the
      insulin suppression test (IST) to quantify IMGU in nondiabetic, overweight/obese volunteers
      to identify those individuals who are sufficiently insulin resistant to be enrolled in this
      study. We will then use the graded glucose infusion technique in these insulin resistant
      subjects to generate specific measures of both GS-IS and I-Cl. Following these baseline
      measurements, salsalate or placebo will be administered for one month to the participants,
      after which time the IST and the graded glucose infusion will be repeated to quantify and
      compare the changes in IMGU, GS-ISR, and I-Cl that have resulted from salsalate versus
      placebo. These results will provide for the first time quantitative data of the effect of
      salicylates on IMGU, GS-ISR, and I-Cl in overweight/obese, insulin resistant, nondiabetic
      individuals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantification of Insulin Action With the Insulin Suppression Test (IST)</measure>
    <time_frame>after treatment for one month</time_frame>
    <description>Compare changes in insulin sensitivity as assesses by the IST before and after treatment between salsalate and placebo group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantification of Insulin Clearance With the Graded Glucose Infusion Test (GGIT)</measure>
    <time_frame>one month on treatment</time_frame>
    <description>compare changes in insulin clearance as assessed by the GGIT before and after treatment with salsalate to placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Pre Diabetes</condition>
  <condition>Insulin Resistant</condition>
  <arm_group>
    <arm_group_label>salsalate 3500mg in 2 divided doses a day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will take 3, 500 mg tablets with breakfast and 4, 500 mg tablets with dinner</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will take 3 placebo tablets with breakfast and 4 placebo tablets with dinner</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salsalate</intervention_name>
    <description>Participants will take 3, 500 mg tablets with breakfast and 4, 500 mg tablets with dinner</description>
    <arm_group_label>salsalate 3500mg in 2 divided doses a day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will take 3 tablets with breakfast and 4 tablets with dinner</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers,

          -  BMI 25-35kg/m2,

          -  Without severe anemia, kidney, liver disease or any current GI ulcers or bleeding

          -  Or on any medication contraindicated with salsalate

        Exclusion Criteria:

          -  Recent history of GI bleed or ulcers,

          -  CVD or on anticoagulants

          -  Severe kidney or liver disease

          -  Allergies to aspirin

          -  Taking aspirin or anti inflammatory medication on a regular basis and cannot be taken
             off for the duration of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerald M Reaven, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2013</study_first_submitted>
  <study_first_submitted_qc>December 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2013</study_first_posted>
  <results_first_submitted>April 1, 2016</results_first_submitted>
  <results_first_submitted_qc>April 1, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 5, 2016</results_first_posted>
  <last_update_submitted>April 1, 2016</last_update_submitted>
  <last_update_submitted_qc>April 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Gerald M Reaven</investigator_full_name>
    <investigator_title>Professor Emeritus</investigator_title>
  </responsible_party>
  <keyword>insulin resistant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Salicylsalicylic acid</mesh_term>
    <mesh_term>Sodium Salicylate</mesh_term>
    <mesh_term>Salicylates</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Salsalate 3500mg in 2 Divided Doses a Day</title>
          <description>Participants will take 3, 500 mg tablets with breakfast and 4, 500 mg tablets with dinner
salsalate: Participants will take 3, 500 mg tablets with breakfast and 4, 500 mg tablets with dinner</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants will take 3 placebo tablets with breakfast and 4 placebo tablets with dinner
Placebo: Participants will take 3 tablets with breakfast and 4 tablets with dinner</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Salsalate 3500mg in 2 Divided Doses a Day</title>
          <description>Participants will take 3, 500 mg tablets with breakfast and 4, 500 mg tablets with dinner
salsalate: Participants will take 3, 500 mg tablets with breakfast and 4, 500 mg tablets with dinner</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants will take 3 placebo tablets with breakfast and 4 placebo tablets with dinner
Placebo: Participants will take 3 tablets with breakfast and 4 tablets with dinner</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="10"/>
                    <measurement group_id="B2" value="54" spread="10"/>
                    <measurement group_id="B3" value="54" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Quantification of Insulin Action With the Insulin Suppression Test (IST)</title>
        <description>Compare changes in insulin sensitivity as assesses by the IST before and after treatment between salsalate and placebo group</description>
        <time_frame>after treatment for one month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Salsalate 3500mg in 2 Divided Doses a Day</title>
            <description>Participants will take 3, 500 mg tablets with breakfast and 4, 500 mg tablets with dinner
salsalate: Participants will take 3, 500 mg tablets with breakfast and 4, 500 mg tablets with dinner</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will take 3 placebo tablets with breakfast and 4 placebo tablets with dinner
Placebo: Participants will take 3 tablets with breakfast and 4 tablets with dinner</description>
          </group>
        </group_list>
        <measure>
          <title>Quantification of Insulin Action With the Insulin Suppression Test (IST)</title>
          <description>Compare changes in insulin sensitivity as assesses by the IST before and after treatment between salsalate and placebo group</description>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3" lower_limit="-10" upper_limit="5"/>
                    <measurement group_id="O2" value="2" lower_limit="-9" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quantification of Insulin Clearance With the Graded Glucose Infusion Test (GGIT)</title>
        <description>compare changes in insulin clearance as assessed by the GGIT before and after treatment with salsalate to placebo</description>
        <time_frame>one month on treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Salsalate 3500mg in 2 Divided Doses a Day</title>
            <description>Participants will take 3, 500 mg tablets with breakfast and 4, 500 mg tablets with dinner
salsalate: Participants will take 3, 500 mg tablets with breakfast and 4, 500 mg tablets with dinner</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will take 3 placebo tablets with breakfast and 4 placebo tablets with dinner
Placebo: Participants will take 3 tablets with breakfast and 4 tablets with dinner</description>
          </group>
        </group_list>
        <measure>
          <title>Quantification of Insulin Clearance With the Graded Glucose Infusion Test (GGIT)</title>
          <description>compare changes in insulin clearance as assessed by the GGIT before and after treatment with salsalate to placebo</description>
          <units>pmol/min x 4h</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6" lower_limit="-12" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="-9" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Salsalate 3500mg in 2 Divided Doses a Day</title>
          <description>Participants will take 3, 500 mg tablets with breakfast and 4, 500 mg tablets with dinner
salsalate: Participants will take 3, 500 mg tablets with breakfast and 4, 500 mg tablets with dinner</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants will take 3 placebo tablets with breakfast and 4 placebo tablets with dinner
Placebo: Participants will take 3 tablets with breakfast and 4 tablets with dinner</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>tinnitus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>3 years</sub_title>
                <description>heartburn</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Gerald Reaven</name_or_title>
      <organization>Stanford Universtiy</organization>
      <phone>650-724-3416</phone>
      <email>greaven@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

